Form 4: Akoya Biosciences Executive Pascal Bamford Reports Stock Transactions
SEC Form 4 Filing
Chief Clinical Officer Pascal Bamford of Akoya Biosciences reports the withholding of shares to cover taxes on restricted stock unit awards.
Summary
- On March 1, 2025, Pascal Bamford, Chief Clinical Officer of Akoya Biosciences, reported transactions involving common stock.
- Shares were withheld to cover taxes on restricted stock unit awards.
- 1,283 shares were withheld at a price of $1.63 to cover taxes on an award granted on February 23, 2023.
- 2,567 shares were withheld at a price of $1.63 to cover taxes on an award granted on February 22, 2024.
- Following these transactions, Bamford directly owns 206,408 shares of Akoya Biosciences common stock.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions related to executive compensation. It doesn't indicate positive or negative sentiment about the company's performance.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and does not provide significant insight into Akoya Biosciences' overall business strategy or competitive positioning within the biotechnology industry.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they relate to tax obligations on executive compensation.
Key Dates
| Date | Description |
|---|---|
| February 23, 2023 | Date of restricted stock unit award that vests in four annual equal installments beginning on March 1, 2024. |
| February 22, 2024 | Date of restricted stock unit award that vests in four annual equal installments beginning on March 1, 2025. |
| March 1, 2024 | First vesting date of the restricted stock unit award granted on February 23, 2023. |
| March 1, 2025 | Date of stock transactions (tax withholding) and first vesting date of the restricted stock unit award granted on February 22, 2024. |
| March 4, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.